Reshma Kewalramani

Last updated
Reshma Kewalramani
Born
Bombay, India
Education Boston University, B.A./M.D. (1998); Harvard General Management Program (2015)
OccupationCEO of Vertex Pharmaceuticals
Years active1998–present
Known forFirst female CEO of a large US biotech company.

Reshma Kewalramani, is the president and chief executive officer of Vertex Pharmaceuticals, a biotechnology company based in Boston, Massachusetts, as of April 1, 2020. [1] [2] [3] She is the first female CEO of a large US biotech company. [2] She was previously the chief medical officer and vice president of global medicines development and medical affairs at Vertex. [4] [5]

Contents

Early life and education

Kewalramani was born in Bombay, India. She and her family immigrated to the US when she was 11 years old. [6]

She graduated in 1998 from the seven-year liberal arts/medical education program at Boston University, [7] Phi Beta Kappa, Summa Cum Laude. [8] She finished her internship and residency at the Massachusetts General Hospital and her fellowship in nephrology at the Massachusetts General Hospital and Brigham and Women's Hospital combined program. [9] After finishing her fellowship in clinical nephrology she did research in transplantation. [8] She graduated from the General Management Program at Harvard Business School in 2015. [4]

Career

Kewalramani began her career as a physician at Massachusetts General Hospital and Brigham and Women's Hospital. [2] [4] She was also a physician at the Massachusetts Eye and Ear Infirmary and the Massachusetts Institute of Technology. [8] She then entered the biopharma sector, working for Amgen for over 12 years, where she held leadership positions in research and development. [1] In 2017 she joined Vertex Pharmaceuticals, and in 2018 became Chief Medical Officer. [10] [2] She assumed the role of president and CEO on April 1, 2020 and is a member of the Vertex Board of Directors. [11]

Since she became CEO, Vertex has developed cystic fibrosis therapy drug Trikafta, [12] APOL1-mediated kidney disease experimental apolipoprotein L1 inhibitor, VX-147, [13] [14] and pain programs into the clinic. [15] The company has also partnered with CRISPR Therapeutics to develop gene-editing therapies for the treatment of sickle cell disease and beta thalassemia. [16]

Boards and awards

Kewalramani is a member of the Massachusetts General Hospital Board of Trustees, the Biomedical Science Careers Program Board [17] and the Boston University School of Medicine Dean's Advisory Board. [18] [19] She was also a member of the board of directors of Ginkgo Bioworks, [20] and was on the inaugural board of directors of the Kidney Health Initiative. [21]

She is the recipient of the American College of Physicians Associates Council Award, the American Medical Women's Association Janet M. Glasgow Memorial Achievement Citation, and the Harvard Medical School Excellence in Teaching Award. Kewalramani is also a Fellow of the American Society of Nephrology and received board certification in Internal Medicine in 2001 and in Nephrology in 2003. [8] In 2019, she received the TiE Boston Healthcare Leadership Award, [22] and was named one of Boston Business Journal's Power 50. [23] In 2020, Kewalramani was named to the inaugural Business Leaders List by Indiaspora, [24] Business Insider’s list of 10 people transforming health care, [25] the PharmaVOICE 100 list of leaders in the life sciences, [26] and Boston Business Journal’s list of Women Who Mean Business. [27] In 2021, she was the recipient of the International Institute of New England’s Golden Door Award and was named a New Englander of the Year by the New England Council. [28] In 2023, she was a recipient of the Hope Visionary award at the 26th annual Biomedical Science Careers Program Evening of Hope benefit in recognition of her passion and commitment to the BSCP students and its mission to help minorities and underrepresented individuals achieve their educational and professional goals in STEM fields. Under her leadership as CEO, Vertex was ranked #2 on The Commonwealth Institute’s Top Women-Led Businesses in Massachusetts in 2021. [29] She was named on Fortune 's list of Most Powerful Women in 2023. [30]

Personal life

Kewalramani lives in Massachusetts, [4] and has twin sons. [31]

Related Research Articles

<span class="mw-page-title-main">Takeda Pharmaceutical Company</span> Japanese pharmaceutical company

The Takeda Pharmaceutical Company Limited is a Japanese multinational pharmaceutical company. It is the third largest pharmaceutical company in Asia, behind Sinopharm and Shanghai Pharmaceuticals, and one of the top 20 largest pharmaceutical companies in the world by revenue. The company has over 49,578 employees worldwide and achieved US$19.299 billion in revenue during the 2018 fiscal year. The company is focused on oncology, rare diseases, neuroscience, gastroenterology, plasma-derived therapies and vaccines. Its headquarters is located in Chuo-ku, Osaka, and it has an office in Nihonbashi, Chuo, Tokyo. In January 2012, Fortune Magazine ranked the Takeda Oncology Company as one of the 100 best companies to work for in the United States. As of 2015, Christophe Weber was appointed as the CEO and president of Takeda.

<span class="mw-page-title-main">Amgen</span> American multinational biopharmaceutical company

Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. As one of the world's largest independent biotechnology companies, Amgen has approximately 24,000 staff in total as of 2022.

<span class="mw-page-title-main">Vertex Pharmaceuticals</span> American pharmaceutical company

Vertex Pharmaceuticals Incorporated is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather than combinatorial chemistry. It maintains headquarters in Boston, Massachusetts, and three research facilities, in San Diego, California, and Milton Park, Oxfordshire, England.

John Mendlein is a biotech executive who has held leadership positions in biotech companies in Boston, San Diego and Toronto.

Michelle Dipp is an American scientist, businesswoman, and investor. She is the co-founder and a managing partner at Biospring Partners and serves on the board of Abzena and Kiniciti.

Daphne Zohar is an American entrepreneur. She is the founder and CEO of Seaport Therapeutics, co-founder of Karuna Therapeutics, and Founding CEO of PureTech Health. She sits on the board of BIO and is a co-founder and host of Biotech Hangout.

<span class="mw-page-title-main">Alexion Pharmaceuticals</span> American healthcare company

Alexion Pharmaceuticals, Inc., a subsidiary of AstraZeneca, is a pharmaceutical company headquartered in Boston, Massachusetts that specializes in orphan drugs to treat rare diseases.

Laurie Hollis Glimcher is an American physician-scientist and former President and CEO of Dana–Farber Cancer Institute. She was elected a member of the American Philosophical Society in 2019. Glimcher has been at the center of controversies related to animal rights activists, excessive corporate payments, and research misconduct. A 2021 investigation by the Boston Globe Spotlight team highlighted Glimcher’s activities on multiple corporate boards, including Bristol Myers Squibb, GlaxoSmithKline, and Analog Devices. After this investigation, Glimcher continued to receive compensation on for-profit boards, while doubling her salary to $4 million per year at Dana-Farber. In October 2024, Glimcher stepped down as President and CEO of Dana-Farber.

Arie S. Belldegrun, FACS, is an Israeli-American urologic oncologist, billionaire businessman and investor.

<span class="mw-page-title-main">Moderna</span> American biotechnology company

Moderna, Inc. is an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts, that focuses on RNA therapeutics, primarily mRNA vaccines. These vaccines use a copy of a molecule called messenger RNA (mRNA) to carry instructions for proteins to produce an immune response. The company's name is derived from the terms "modified", "RNA", and "modern".

Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list.

<span class="mw-page-title-main">OS Fund</span> American venture-capital fund

OS Fund is an American venture capital fund that invests in early-stage science and technology companies.

<span class="mw-page-title-main">Henri Termeer</span> American businessman (1946–2017)

Henri A. Termeer was a Dutch biotechnology executive and entrepreneur who is considered a pioneer in corporate strategy in the biotechnology industry for his tenure as CEO at Genzyme. Termeer created a business model adopted by many others in the biotech industry by garnering steep prices— mainly from insurers and government payers— for therapies for rare genetic disorders known as orphan diseases that mainly affect children. Genzyme uses biological processes to manufacture drugs that are not easily copied by generic-drug makers. The drugs are also protected by orphan drug acts in various countries which provides extensive protection from competition and ensures coverage by publicly funded insurers. As CEO of Genzyme from 1981 to 2011, he developed corporate strategies for growth including optimizing institutional embeddedness nurturing vast networks of influential groups and clusters: doctors, private equity, patient-groups, insurance, healthcare umbrella organizations, state and local government, and alumni. Termeer was "connected to 311 board members in 17 different organizations across 20 different industries" He has the legacy of being the "longest-serving CEO in the biotechnology industry.

<span class="mw-page-title-main">Eve Slater</span> American physician (born 1945)

Eve Elizabeth Slater is an American physician who served as the United States Assistant Secretary for Health and Human Services under President George W. Bush from 2002 to 2003. Slater received her A.B. from Vassar College in 1967 and M.D. from the Columbia University College of Physicians and Surgeons in 1971. She completed residency in internal medicine and fellowship in cardiology at the Massachusetts General Hospital, Boston, MA.In 1976, she was appointed the Chief Resident in Medicine at Massachusetts General Hospital, the first woman to appointed to this position. Dr. Slater is currently Professor of Clinical Medicine at Columbia Vagelos College of Physicians and Surgeons (P&S), where she has taught for over 35 years. She is board certified in internal medicine and cardiology and a fellow of the American College of Cardiology.(FACC). At MGH, she led the Hypertension Unit, as Assistant Professor of Medicine. Harvard Medical School.

Harvey J. Berger is an American physician-scientist, entrepreneur and biotechnology executive. He was the founder and chairman and chief executive officer of ARIAD Pharmaceuticals, Inc. for 25 years, starting in 1991 and became advisor to the board in 2016. He was also executive chairman at Medinol, Inc from 2017 to 2018. In February 2018, Berger was appointed to the Dana–Farber Cancer Institute Board of Trustees.

<span class="mw-page-title-main">Biotechnology industry in Boston</span>

Greater Boston, primarily Boston and Cambridge, is home to more than 1,000 biotechnology companies, ranging from small start-ups to billion-dollar pharmaceutical companies. The many universities in the area give the region a large network of scientists.

Ginkgo Bioworks is an American biotech company founded in 2008 by five scientists from MIT, headed by Jason Kelly. The company specializes in using genetic engineering to produce bacteria with industrial applications for other biotech companies, saving other companies the cost of reproducing the initial stages of design in synthetic biology. The self-proclaimed "Organism Company" was one of the world's largest privately held biotech companies, valued at $4.2 billion in 2019. It raised $290 million in September and $350 million in October of that year. Ginkgo Bioworks went public on the New York Stock Exchange via a SPAC merger on September 17, 2021.

<span class="mw-page-title-main">Joshua Boger</span> Organic chemist and the founder of Vertex Pharmaceuticals

Joshua S. Boger is an organic chemist and the founder of Vertex Pharmaceuticals Incorporated. He is considered a pioneer in the field of structure-based rational drug design. Drugs developed include amprenavir, an HIV protease inhibitor; telaprevir, a protease inhibitor for treatment of hepatitis C; and Kalydeco, for the treatment of cystic fibrosis. In 2003, Vertex was listed as one of forty worldwide Technology Pioneers by the World Economic Forum. As of 2012, Boger became executive chairman of Alkeus Pharmaceuticals.

<span class="mw-page-title-main">Jeffrey Leiden</span> CEO of biotechnology company

Jeffrey Leiden is an American physician, scientist and businessman who is the executive chairman of Vertex Pharmaceuticals, a biotechnology company based in Boston, Massachusetts. He was initially appointed to the board of directors of the company in 2009 and was CEO and president from February 2012 to March 2020.

<span class="mw-page-title-main">CRISPR Therapeutics</span> Swiss-American biotechnology company

CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland. It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases. The company has approximately 500 employees and has offices in Zug, Switzerland, Boston, Massachusetts, San Francisco, California and London, United Kingdom. Its manufacturing facility in Framingham, Massachusetts won the Facilities of the Year Award (FOYA) award in 2022. The company’s lead program, exagamglogene autotemcel, or exa-cel, was granted regulatory approval by the US Food and Drug Administration (FDA) in December 2023.

References

  1. 1 2 Toy, Sarah. "Vertex Pharmaceuticals names Chief Medical Officer Reshma Kewalramani as new CEO". MarketWatch. Retrieved 2020-03-15.
  2. 1 2 3 4 "For biotech industry, a milestone: Vertex names woman as president, CEO - The Boston Globe". BostonGlobe.com. Retrieved 2020-03-15.
  3. ↑ DeAngelis, Allison (2 April 2020). "VERTEX 3.0: One of the area's largest biotechs enters new era of leadership, drug development". BizJournals. Retrieved 5 April 2020.
  4. 1 2 3 4 Singh, Rishi (August 2019). "Trail-blazing MED Alum to Lead Vertex Pharmaceuticals". Boston University. Retrieved 2020-03-15.
  5. ↑ Surdez, Steven (2019-08-27). "These Female Executives Set the Standard of Excellence in the Biohealth Capital Region · BioBuzz". BioBuzz. Retrieved 2020-03-15.
  6. ↑ "Alumni Profile: Reshma Kewalramani, MD". Boston University Medicine. Winter 2020: 33–34.
  7. ↑ "Boston University Medicine – Winter 2020". Issuu. January 2020. p. 33. Retrieved 2020-03-16.
  8. 1 2 3 4 "American Society of Nephrology | About ASN - Reshma Kewalramani, MD, FASN". www.asn-online.org. Retrieved 2020-03-15.
  9. ↑ ALBANESE, Compiled by GIOVANNI Jr. "Career Briefs: Dr. Deepika Kalisetti Joins Commonwealth Health Physician Network". India West. Retrieved 2020-03-16.
  10. ↑ Terry, Mark (26 February 2018). "Vertex Pharmaceuticals Appoints Reshma Kewalramani as New CMO". BioSpace.
  11. ↑ Engl, India New; News (2019-07-25). "Vertex Pharmaceuticals Appoints Dr. Reshma Kewalramani as New CEO". INDIA New England News. Retrieved 2020-03-15.{{cite web}}: |last2= has generic name (help)
  12. ↑ Choudhary, Vidhi (10 March 2022). "Vertex Pharma Has a Cystic Fibrosis Drug That Rivals Envy". TheStreet.
  13. ↑ Armstrong, Madeleine (1 December 2021). "Vertex finally catches a break". Evaluate Vantage.
  14. ↑ Pagliarulo, Ned (22 March 2022). "Vertex plans path to FDA for top drug prospect". BioPharmaDive.
  15. ↑ Fidler, Ben (22 September 2021). "This is the time to double down': Top Vertex executives defend research plan as pressure builds". BioPharmaDive.
  16. ↑ Garde, Damian (11 June 2021). "A CRISPR treatment for blood diseases shows curative promise in small study". STAT News.
  17. ↑ "Leadership". BSCP.com.
  18. ↑ "Giving/Board of Trustees". giving.massgeneral.org.
  19. ↑ "BUSM Dean's Advisory Board". bumc.bu.edu.
  20. ↑ "Vertex CEO Dr. Kewalramani to Join Ginkgo Board". ginkgobioworks.com. Ginkgo Bioworks. 3 August 2021.
  21. ↑ "Dr. Reshma Kewalramani named incoming president and CEO of Vertex Pharmaceuticals, former member ASN KHI Board of Directors". Kidney News Online. 26 July 2019.
  22. ↑ Reporter, India-West Staff. "TiE Boston Recognizes Entrepreneurs at 2019 Gala: Lifetime Achievement Award for Indian American edX CEO Anant Agarwal". India West. Retrieved 2020-04-05.
  23. ↑ "Meet BBJ's Power 50: The region's most influential leaders". www.bizjournals.com. 26 September 2019. Retrieved 2020-04-05.
  24. ↑ "2020 Indiaspora Business Leaders List". lists.indiaspora.org. Retrieved 2020-07-12.
  25. ↑ Lee, Vivian S. (2020). "100 People Transforming Business in North America". Business Insider.
  26. ↑ "PharmaVOICE 100 Who's on the List - By Category". PharmaVOICE. 1 August 2020.
  27. ↑ "Here are the BBJ's 2020 Women Who Mean Business honorees". Boston Business Journal. 15 October 2020.
  28. ↑ "NEC to Honor Historic All-Female Lineup of 2021 New Englanders of the Year". The New England Council. 2021.
  29. ↑ "The 2021 Top 100 Women-Led Businesses". Boston Globe. 5 November 2021.
  30. ↑ "Most Powerful Women". Fortune.
  31. ↑ "For biotech industry, a milestone: Vertex names woman as president, CEO - The Boston Globe". BostonGlobe.com. Retrieved 2020-04-05.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.